Compare AEG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AEG | ABVX |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | Netherlands | France |
| Employees | 15500 | 67 |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.7B |
| IPO Year | N/A | N/A |
| Metric | AEG | ABVX |
|---|---|---|
| Price | $6.80 | $120.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $130.85 |
| AVG Volume (30 Days) | ★ 5.6M | 743.8K |
| Earning Date | 02-09-2023 | 03-23-2026 |
| Dividend Yield | ★ 5.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $175.15 | N/A |
| Revenue Next Year | $1.22 | $0.22 |
| P/E Ratio | $7.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.42 | $4.77 |
| 52 Week High | $8.15 | $148.83 |
| Indicator | AEG | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 51.22 |
| Support Level | N/A | $106.37 |
| Resistance Level | $8.02 | $131.27 |
| Average True Range (ATR) | 0.15 | 5.07 |
| MACD | -0.01 | 0.90 |
| Stochastic Oscillator | 10.31 | 69.98 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle funds into capital-light and more predictable strategic businesses.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.